Last reviewed · How we verify
Fluticasone Propionate 500mcg
At a glance
| Generic name | Fluticasone Propionate 500mcg |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution (PHASE1)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
- Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (PHASE4)
- A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (PHASE1)
- A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP)) (PHASE3)
- SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (PHASE4)
- Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Propionate 500mcg CI brief — competitive landscape report
- Fluticasone Propionate 500mcg updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI